Peter G. Milner, MD, FACC, Co-Founder & Director

Dr. Milner co-founded Optivia in 2007. In 1997 Peter co-founded ARYx Therapeutics (NASDAQ:ARYX) where he served as CEO until 2005, and President from 2005 to 2010 with overall responsibility for R&D. In 1990 he co-founded CV Therapeutics (NASDAQ:CVTX), where as a member of senior management from 1992-1996 he in-licensed and co-invented several successful pharmaceuticals. CV Therapeutics was acquired by Gilead for $1.5B in cash in 2009. In 2005, Peter was instrumental in restructuring his family pharmaceutical company ML Laboratories (MLB.LSE) and its subsequent merger to form Vectura (VEC.LSE), a profitable company and one of the worlds leading makers of inhaled products.

Prior to 1992, Peter was as an assistant professor of medicine at Washington University in St. Louis. His research led to the discovery of pleiotrophin (PTN), a novel growth factor that regulates stem cell differentiation, organ development, and the epithelial mesenchymal transition (EMT). He was educated at the University of Liverpool receiving his medical degree in 1980, before completing his postgraduate training at Johns Hopkins Hospital, The University of Virginia, and Washington University in St. Louis. Peter is co-inventor on 48 issued patents, and an author of 28 original scientific articles in Science, Biochemistry, Circulation, Cancer, JCI, and JBC. He is a Fellow of the American College of Cardiology (FACC), and a board certified physician and cardiologist. He serves as adjunct clinical faculty at Stanford University School of Medicine, and as a board member of the California Healthcare Institute (CHI).